A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.
Appendix 1 - Case Definitions
The following table displays the case definitions for vaccine preventable diseases notified to the National Notifiable Diseases Surveillance System in 1999. If you are not able to access these data please e-mail cdi.editor@health.gov.au
Appendix 1f. Case definitions and ICD-10 code for notifiable diseases reported to NNDSS in 1999, vaccine preventable diseases
Disease |
Case definition (NHMRC 1994) |
ICD-10 code(s) |
|---|---|---|
| Diphtheria | Isolation of toxigenic Corynebacterium diphtheriae
AND pharyngitis and/or laryngitis (with or without a membrane OR toxic (cardiac or neurological) symptoms |
A36 |
| Haemophilus influenzae type B | An invasive clinically compatible illness (meningitis, epiglottitis, cellulitis, septic arthritis, osteomyelitis, pneumonia, pericarditis or septicaemia)
AND either the isolation of Haemophilus influenzae type b (Hib) from blood OR detection of Hib antigen (in a clinical case) OR detection of Gram-negative bacteria where the organism fails to grow in a clinical case |
A41.3, GO0.0, JO5.1 |
| Measles | An illness characterised by all the following features: a generalised maculopapular rash lasting three or more days
AND a fever (at least 38oC if measured) AND cough or coryza or conjunctivitis or Koplik spots OR Demonstration of measles specific IgM antibody OR A four-fold or greater change in measles antibody titre between acute and convalescent-phase sera obtained at least 2 weeks apart, with tests preferably conducted in parallel at the same laboratory OR Isolation of the measles virus from a clinical specimen OR A clinically compatible case epidemiologically related to another case |
BO5 |
| Mumps | Isolation of mumps virus from a clinical specimen
OR significant rise in mumps antibody level by any standard serological assay, except following immunisation OR a clinically compatible illness (unilateral or bilateral swelling of the parotid or other salivary glands lasting 2 days or more without other apparent cause) |
B26 |
| Pertussis | Isolation of Bordetella pertussis from a clinical specimen
OR elevated Bordetella pertussis-specific IgA in serum or B. pertussis antigen in a nasopharyngeal specimen using immunofluorescence with a history of clinically compatible illness |
A37 |
| Poliomyelitis | Acute onset of a flaccid paralysis of one or more limbs with decreased or absent tendon reflexes in the affected limbs without other apparent cause, without sensory or cognitive loss | A80 |
| Rubella | A generalised maculopapular rash and fever
AND one or more of: arthralgia/arthritis OR lymphadenopathy OR conjunctivitis AND an epidemiological link to a confirmed case OR demonstration of rubella-specific IgM antibody, except following immunisation OR a four-fold or greater change in rubella antibody titre between acute and convalescent-phase sera obtained at least 2 weeks apart |
BO6 |
| Tetanus | A clinically compatible illness without other apparent cause, with or without a history of injury and with or without laboratory evidence of the organism or its toxin | A33 |
This article was published in Communicable Diseases Intelligence Volume 25, No 4, November 2001.
CDI Search
Communicable Diseases Intelligence subscriptions
Sign-up to email updates: Subscribe Now
Communicable Diseases Surveillance
This issue - Vol 25, No 4, November 2001
NNDSS 1999 Annual Report
Communicable Diseases Intelligence